Immediate Impact
61 standout
Citing Papers
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Works of Junichi Tomomatsu being referenced
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
2021
Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Junichi Tomomatsu | 223 | 154 | 61 | 104 | 49 | 414 | |
| Hae Su Kim | 262 | 170 | 42 | 144 | 25 | 497 | |
| Ali Ayberk Beşen | 206 | 132 | 64 | 35 | 60 | 461 | |
| Umut Dişel | 145 | 78 | 37 | 152 | 46 | 459 | |
| Yu Fujiwara | 280 | 98 | 32 | 90 | 53 | 481 | |
| Ik Joon Choi | 95 | 69 | 57 | 77 | 33 | 415 | |
| Erika Tóth | 204 | 97 | 33 | 89 | 63 | 432 | |
| Tetsuya Urasaki | 202 | 106 | 31 | 74 | 53 | 405 | |
| Sehhoon Park | 270 | 116 | 13 | 90 | 49 | 466 | |
| Yanfen Feng | 191 | 84 | 22 | 127 | 39 | 411 | |
| Tobias Bartscht | 197 | 170 | 32 | 68 | 63 | 455 |
All Works
Loading papers...